Titre : Industrie pharmaceutique

Industrie pharmaceutique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Data Accuracy
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Industrie pharmaceutique : Questions médicales les plus fréquentes", "headline": "Industrie pharmaceutique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Industrie pharmaceutique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-13", "dateModified": "2025-04-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Industrie pharmaceutique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Secteur secondaire", "url": "https://questionsmedicales.fr/mesh/D066192", "about": { "@type": "MedicalCondition", "name": "Secteur secondaire", "code": { "@type": "MedicalCode", "code": "D066192", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.576.655" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Médicament orphelin", "alternateName": "Orphan Drug Production", "url": "https://questionsmedicales.fr/mesh/D009965", "about": { "@type": "MedicalCondition", "name": "Médicament orphelin", "code": { "@type": "MedicalCode", "code": "D009965", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.576.655.750.600" } } } ], "about": { "@type": "MedicalCondition", "name": "Industrie pharmaceutique", "alternateName": "Drug Industry", "code": { "@type": "MedicalCode", "code": "D004345", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Beatriz G de la Torre", "url": "https://questionsmedicales.fr/author/Beatriz%20G%20de%20la%20Torre", "affiliation": { "@type": "Organization", "name": "KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa." } }, { "@type": "Person", "name": "Fernando Albericio", "url": "https://questionsmedicales.fr/author/Fernando%20Albericio", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa." } }, { "@type": "Person", "name": "Christophe Tistaert", "url": "https://questionsmedicales.fr/author/Christophe%20Tistaert", "affiliation": { "@type": "Organization", "name": "Small Molecules Pharmaceutical Development, Drug Product Development, Biopharmaceutics, Janssen Research and Development, Beerse, Belgium." } }, { "@type": "Person", "name": "Tycho Heimbach", "url": "https://questionsmedicales.fr/author/Tycho%20Heimbach", "affiliation": { "@type": "Organization", "name": "Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936." } }, { "@type": "Person", "name": "Joel Lexchin", "url": "https://questionsmedicales.fr/author/Joel%20Lexchin", "affiliation": { "@type": "Organization", "name": "School of Health Policy and Management, York University, Toronto, ON, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Initiatives, Concepts, and Implementation Practices of the Findable, Accessible, Interoperable, and Reusable Data Principles in Health Data Stewardship: Scoping Review.", "datePublished": "2023-08-28", "url": "https://questionsmedicales.fr/article/37639292", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/45013" } }, { "@type": "ScholarlyArticle", "name": "Equity and bias in electronic health records data.", "datePublished": "2023-05-22", "url": "https://questionsmedicales.fr/article/37225122", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cct.2023.107238" } }, { "@type": "ScholarlyArticle", "name": "Data quality and autism: Issues and potential impacts.", "datePublished": "2022-11-28", "url": "https://questionsmedicales.fr/article/36455477", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijmedinf.2022.104938" } }, { "@type": "ScholarlyArticle", "name": "The Detection of Date Shifting in Real-World Data.", "datePublished": "2023-07-17", "url": "https://questionsmedicales.fr/article/37459888", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-2130-2197" } }, { "@type": "ScholarlyArticle", "name": "Tailoring Rule-Based Data Quality Assessment to the Patient-Centered Outcomes Research Network (PCORnet) Common Data Model (CDM).", "datePublished": "2023-04-29", "url": "https://questionsmedicales.fr/article/37128433", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": null } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Industrie", "item": "https://questionsmedicales.fr/mesh/D007221" }, { "@type": "ListItem", "position": 4, "name": "Secteur secondaire", "item": "https://questionsmedicales.fr/mesh/D066192" }, { "@type": "ListItem", "position": 5, "name": "Industrie pharmaceutique", "item": "https://questionsmedicales.fr/mesh/D004345" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Industrie pharmaceutique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Industrie pharmaceutique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Industrie pharmaceutique", "description": "Comment évaluer l'efficacité d'un médicament ?\nQu'est-ce qu'une étude de phase III ?\nQuels sont les critères d'inclusion dans un essai ?\nComment sont mesurés les effets secondaires ?\nQu'est-ce qu'un placebo ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Data+Accuracy&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Industrie pharmaceutique", "description": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?\nComment reconnaître une allergie médicamenteuse ?\nQuels signes d'overdose sont fréquents ?\nQuels symptômes d'une interaction médicamenteuse ?\nComment identifier un effet secondaire rare ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Data+Accuracy&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Industrie pharmaceutique", "description": "Comment prévenir les effets indésirables des médicaments ?\nQuelles sont les bonnes pratiques de prescription ?\nComment sensibiliser aux risques médicamenteux ?\nQuels conseils pour éviter les interactions médicamenteuses ?\nComment gérer les prescriptions multiples ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Data+Accuracy&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Industrie pharmaceutique", "description": "Comment sont développés les nouveaux médicaments ?\nQu'est-ce qu'un médicament générique ?\nComment fonctionne la thérapie ciblée ?\nQu'est-ce qu'un médicament orphelin ?\nComment se déroule la mise sur le marché d'un médicament ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Data+Accuracy&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Industrie pharmaceutique", "description": "Quelles complications peuvent survenir avec les médicaments ?\nComment gérer une réaction allergique grave ?\nQuels sont les risques de surdosage ?\nComment prévenir les complications liées aux traitements ?\nQuelles sont les complications des médicaments anticancéreux ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Data+Accuracy&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Industrie pharmaceutique", "description": "Quels facteurs augmentent le risque d'effets secondaires ?\nComment l'alcool influence-t-il les médicaments ?\nQuels médicaments sont à risque pour les personnes âgées ?\nComment les maladies chroniques affectent-elles la médication ?\nQuels sont les risques liés à l'automédication ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Data+Accuracy&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'efficacité d'un médicament ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par des essais cliniques et des études de marché." } }, { "@type": "Question", "name": "Qu'est-ce qu'une étude de phase III ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "C'est une étude qui teste l'efficacité d'un médicament sur un grand nombre de patients." } }, { "@type": "Question", "name": "Quels sont les critères d'inclusion dans un essai ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères d'inclusion définissent les caractéristiques des participants éligibles." } }, { "@type": "Question", "name": "Comment sont mesurés les effets secondaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont mesurés par des rapports de patients et des études post-commercialisation." } }, { "@type": "Question", "name": "Qu'est-ce qu'un placebo ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un placebo est un traitement inactif utilisé comme référence dans les essais cliniques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des éruptions cutanées, des nausées ou des vertiges peuvent survenir." } }, { "@type": "Question", "name": "Comment reconnaître une allergie médicamenteuse ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les allergies se manifestent par des démangeaisons, des rougeurs ou un gonflement." } }, { "@type": "Question", "name": "Quels signes d'overdose sont fréquents ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence, et troubles respiratoires." } }, { "@type": "Question", "name": "Quels symptômes d'une interaction médicamenteuse ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des vertiges, des palpitations ou des troubles digestifs peuvent apparaître." } }, { "@type": "Question", "name": "Comment identifier un effet secondaire rare ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires rares sont souvent identifiés par des études de pharmacovigilance." } }, { "@type": "Question", "name": "Comment prévenir les effets indésirables des médicaments ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par une prescription appropriée et une surveillance des patients." } }, { "@type": "Question", "name": "Quelles sont les bonnes pratiques de prescription ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les bonnes pratiques incluent l'évaluation des antécédents médicaux et la communication avec le patient." } }, { "@type": "Question", "name": "Comment sensibiliser aux risques médicamenteux ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation se fait par des campagnes d'information et des formations pour les professionnels." } }, { "@type": "Question", "name": "Quels conseils pour éviter les interactions médicamenteuses ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de toujours informer le médecin de tous les médicaments pris, y compris les OTC." } }, { "@type": "Question", "name": "Comment gérer les prescriptions multiples ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique une coordination entre les différents prescripteurs et un suivi régulier." } }, { "@type": "Question", "name": "Comment sont développés les nouveaux médicaments ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les nouveaux médicaments sont développés par la recherche, les essais cliniques et l'approbation réglementaire." } }, { "@type": "Question", "name": "Qu'est-ce qu'un médicament générique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Un médicament générique est une version d'un médicament de marque, généralement moins coûteuse." } }, { "@type": "Question", "name": "Comment fonctionne la thérapie ciblée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie ciblée agit sur des molécules spécifiques impliquées dans la maladie." } }, { "@type": "Question", "name": "Qu'est-ce qu'un médicament orphelin ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Un médicament orphelin est destiné à traiter des maladies rares, souvent sans alternatives." } }, { "@type": "Question", "name": "Comment se déroule la mise sur le marché d'un médicament ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La mise sur le marché nécessite des essais cliniques, une évaluation réglementaire et une approbation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les médicaments ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des réactions allergiques, des surdosages et des interactions." } }, { "@type": "Question", "name": "Comment gérer une réaction allergique grave ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une réaction allergique grave nécessite une intervention médicale immédiate, comme l'adrénaline." } }, { "@type": "Question", "name": "Quels sont les risques de surdosage ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le surdosage peut entraîner des dommages organiques, des troubles neurologiques ou la mort." } }, { "@type": "Question", "name": "Comment prévenir les complications liées aux traitements ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un suivi régulier et une évaluation des effets secondaires." } }, { "@type": "Question", "name": "Quelles sont les complications des médicaments anticancéreux ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des nausées et des troubles sanguins." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, le poids, les maladies préexistantes et les interactions médicamenteuses augmentent le risque." } }, { "@type": "Question", "name": "Comment l'alcool influence-t-il les médicaments ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'alcool peut intensifier les effets des médicaments, augmentant le risque d'effets indésirables." } }, { "@type": "Question", "name": "Quels médicaments sont à risque pour les personnes âgées ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les médicaments à risque incluent les sédatifs, les anticoagulants et certains analgésiques." } }, { "@type": "Question", "name": "Comment les maladies chroniques affectent-elles la médication ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Les maladies chroniques peuvent modifier la réponse aux médicaments et augmenter les effets secondaires." } }, { "@type": "Question", "name": "Quels sont les risques liés à l'automédication ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'automédication peut entraîner des interactions, des surdosages et des retards de traitement." } } ] } ] }

Sources (10000 au total)

Initiatives, Concepts, and Implementation Practices of the Findable, Accessible, Interoperable, and Reusable Data Principles in Health Data Stewardship: Scoping Review.

Thorough data stewardship is a key enabler of comprehensive health research. Processes such as data collection, storage, access, sharing, and analytics require researchers to follow elaborate data man... This scoping review identifies and discusses concepts, approaches, implementation experiences, and lessons learned in FAIR initiatives in health research data.... The Arksey and O'Malley stage-based methodological framework for scoping reviews was applied. PubMed, Web of Science, and Google Scholar were searched to access relevant publications. Articles written... A total of 2.18% (34/1561) of the screened articles were included in the final review. The authors reported FAIRification approaches, which include interpolation, inclusion of comprehensive data dicti... This work summarises projects, tools, and workflows for the FAIRification of health research data. The comprehensive review shows that implementing the FAIR concept in health data stewardship carries ... RR2-10.2196/22505....

Data quality and autism: Issues and potential impacts.

Large healthcare datasets can provide insight that has the potential to improve outcomes for patients. However, it is important to understand the strengths and limitations of such datasets so that the... Data were extracted from the HES database for the period 1st April 2013 to 31st March 2021 for patients with a diagnosis of autism. First spells in hospital during the study period were identified for... Data were available for 172,324 unique patients who had been recorded as having an autism diagnosis on first admission. In total, 43.7 % of subsequent spells were found to have inconsistencies. The fe... Data inconsistencies in the HES database were relatively common in autistic patients and were associated a number of patient and hospital admission characteristics. Such inconsistencies have the poten...

The Detection of Date Shifting in Real-World Data.

Analysis of health care real-world data (RWD) provides an opportunity to observe the actual patient diagnostic, treatment, and outcome events. However, researchers should understand the possible limit... A methodology for detecting the presence of shifted dates in RWD was developed by considering various approaches to confirm the expected occurrences of medical events, including unique temporal occurr... Twenty-eight of the 71 HCOs analyzed were predicted by methodology and confirmed by their data providers to have shifted data. Likewise, 39 were predicted and confirmed to not have shifted data. With ... The presence of date shifting for U.S. HCOs may be reliably detected assessing whether the routine exams should always occur on weekdays....

Assessing the quality of emergency department data for injury surveillance in Victoria, Australia: a comparative analysis of two Victorian hospital data sources.

The emergency department (ED) is pivotal in treating serious injuries, making it a valuable source for population-based injury surveillance. In Victoria, information that is relevant to injury surveil... A retrospective observational study of administrative healthcare data.... VEMD and VAED data from July 2014 to June 2019 were compared. Including only hospitals contributing to both datasets, cases that (1) arrived at the ED and (2) were subsequently admitted, were selected... While the overall number of cases was similar, VAED outnumbered VEMD cases (414 630 vs 404 608), suggesting potential under-reporting of injuries in the ED. Age-related differences indicated a relativ... Injury cases were more numerous in the VAED than in the VEMD even though the number is expected to be equal based on case selection. Older patients were under-represented in the VEMD; this could partl...

Improving the Data Quality of Untargeted Metabolomics through a Targeted Data-Dependent Acquisition Based on an Inclusion List of Differential and Preidentified Ions.

Metabolomics based on high-resolution mass spectrometry has become a powerful technique in biomedical research. The development of various analytical tools and online libraries has promoted the identi...

Consistency as a Data Quality Measure for German Corona Consensus Items Mapped from National Pandemic Cohort Network Data Collections.

As a national effort to better understand the current pandemic, three cohorts collect sociodemographic and clinical data from coronavirus disease 2019 (COVID-19) patients from different target populat... The goal of this work is to assure high consistency of research data mapped to the GECCO data model. In particular, it aims at identifying contradictions within interdependent GECCO data items of the ... All suitable data items from each of the three NAPKON cohorts are mapped to the GECCO items. A consistency assessment tool (dqGecco) is implemented, following the design of an existing quality assessm... Our consistency assessment tool helped in correcting the mapping procedure and reveals remaining contradictory value combinations within COVID-19 symptoms, vital signs, and COVID-19 severity. Consiste... An efficient and portable tool capable of discovering inconsistencies in the COVID-19 domain has been developed and applied to three different cohorts. As the GECCO dataset is employed in different pl...

Routine use of DHIS2 data: a scoping review.

In regard to health service planning and delivery, the use of information at different levels in the health system is vital, ranging from the influencing of policy to the programming of action to the ... The five-stage approach of Arksey and O'Malley progressed by Levac et al. and Peters was followed. Three databases (PubMed, Web of Science and Embase) were searched, along with relevant conference pro... Overall, DHIS2 data are being used but there are few detailed descriptions of this usage in peer reviewed or grey literature. We find that, commonly, there exists a centralised versus decentralised pa... We conclude with some suggestions for a way forward, namely: i) the need to document in more detail and share how data are being used, ii) the need to investigate how data were created and who uses su...

"We don't trust all data coming from all facilities": factors influencing the quality of care network data quality in Ethiopia.

Good quality data are a key to quality health care. In 2017, WHO has launched the Quality of Care Network (QCN) to reduce maternal, newborn and stillbirth mortality via learning and sharing networks. ... This paper seeks to explore how QCN has contributed to improving data quality and to identify factors influencing quality of data in Ethiopia.... We conducted a qualitative study in selected QCN facilities in Ethiopia using key informant interview and observation methods. We interviewed 40 people at national, sub-national and facility levels. N... There was a general perception that QCN had improved health data documentation and use in the learning facilities, achieved through coaching, learning and building from pre-existing initiatives. QCN a... There is evidence of QCN's contribution to improving data awareness. But a lack of inclusive engagement of actors, alignment and limited skill for data collection and analysis continued to affect data...